Central nervous system complications associates...
Immune checkpoint inhibitors (ICIs) are novel oncological treatments which show remarkable clinical efficacy in various malignant tumours, including melanoma and lung cancer. ICIs act by enhancing the patient’s immune system to fight cancer. This action is possible because these monoclonal antibodies (Abs) have the ability to block intrinsic downregulators of immunity. By increasing the activity of the immune system, ICIs may trigger a number of immune-related side effects, which can involve any organ or system, including the nervous system.
Moreover, it has been shown, in both experimental and clinical settings, that ICIs can induce paraneoplastic neurological syndromes (PNS). In this retrospective study, they describe the clinical spectrum, treatment and outcome of CNS-ICI.
